TGA approval of Skyrizi
For Fellows and Trainees
For Health Professionals
Posted 10 months ago
The Therapeutic Goods Adminisation (TGA) has granted regulartory approval for Skyrizi (Risankizumab) for the treatment of moderate to severe plaque psoriasis in adults who are candidates for phototherapy or systemic therapy.
It is an IL-23 blocking biological agent. Note that Skyrizi is not listed on the Pharmaceutical Benefits Scheme (PBS).